腺素受体的药理学:最近的进展
Fabrizio Vincenzi1, Silvia Pasquini2, Chiara Contri1
1Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
Biomolecules
|September 28, 2023
概括
针对腺受体 (ARs) 的药物开发在各种疾病中取得了显著进展. 尽管在选择性向方面存在挑战,但新的带和策略提供了有前途的治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 氨酸受体 (AR) 是已知的药理标,具有广泛的治疗潜力.
- 它们的广泛分布对选择性和特定地点的药物开发提出了挑战.
- 抗逆转录蛋白涉及到许多生理和病理生理过程.
研究的目的:
- 审查最近开发调节腺受体的药物的进展.
- 突出AR调制的新机制和治疗应用.
- 讨论AR激活的新配体和创新策略.
主要方法:
- 关于腺受体调节器的临床前和临床研究的综合性综述.
- 分析最近关于AR在各种疾病中的作用的研究.
- 检查新型连接体,激活策略和信号通路.
主要成果:
- 在开发调节ARs的药物方面取得了重大进展.
- 证据支持AR调制用于治疗中枢神经系统疾病,心血管和代谢疾病,炎症疾病和癌症.
- 识别参与AR功能中的新机制和信号通路.
结论:
- 氨酸受体调节对治疗各种疾病具有相当大的前景.
- 最近的研究提供了令人信服的证据,证明了新型AR向药物的有效性.
- 选择性AR配体和策略的进一步开发对于临床转化至关重要.
关键词:
A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1 A1A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2A A2AA2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2B A2BA3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3 A3氨酸 (Adenosine) 是一种氨酸.腺素受体的受体它具有治疗潜力.相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
764
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
764
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
906
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
906
Adrenergic Agonists: Direct-Acting Agents
1.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.6K
Adrenergic Agonists: Indirect-Acting Agents
1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K


